drugset / Trial / NCT01043380

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

NCT01043380 ↗

Phase 4 Completed 245 enrolled Kumamoto University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound \[IVUS\] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.

Timeline

Start
2010-01
Primary completion
2014-03
Completion
2014-09

Outcome

Met primary endpoint

paper absolute change in PAV did show superiority for the dual lipid-lowering strategy PMID 26227186 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg —
Subject Ezetimibe Unknown 10 mg —